Closed-loop insulin therapy improves glycemic control in children aged Andrew Dauber  1 , Liat Corcia, Jason Safer, Michael S D Agus, Sara Einis, Garry M Steil Affiliations Expand Affiliation 1 Division of Endocrinology, Boston Children’s Hospital, Boston, MA, USA. PMID: 23033237 PMCID: PMC3554296 DOI: 10.2337/dc12-1079 Free PMC article Item in Clipboard

Andrew Dauber, Liat Corcia, Jason Safer, Michael S D Agus, Sara Einis, Garry M Steil, Andrew Dauber, Liat Corcia, Jason Safer, Michael S D Agus, Sara Einis, Garry M Steil

Abstract

Objective: To assess the possibility of improving nocturnal glycemic control as well as meal glycemic response using closed-loop therapy in children aged <7 years.

Research design and methods: This was a randomized controlled crossover trial comparing closed-loop with standard open-loop insulin pump therapy performed in an inpatient clinical research center. Ten subjects aged <7 years with type 1 diabetes for >6 months treated with insulin pump therapy were studied. Closed-loop therapy and standard open-loop therapy were compared from 10:00 p.m. to 12:00 p.m. on 2 consecutive days. The primary outcome was plasma glucose time in range (110-200 mg/dL) during the night (10:00 p.m.-8:00 a.m.). Secondary outcomes included peak postprandial glucose levels, incidence of hypoglycemia, degree of hyperglycemia, and prelunch glucose levels.

Results: A trend toward a higher mean nocturnal time within target range was noted for closed- versus open-loop therapy, although not reaching statistical significance (5.3 vs. 3.2 h, P = 0.12). There was no difference in peak postprandial glucose or number of episodes of hypoglycemia. There was significant improvement in time spent >300 mg/dL overnight with closed-loop therapy (0.18 vs. 1.3 h, P = 0.035) and the total area under the curve of glucose >200 mg/dL (P = 0.049). Closed-loop therapy returned prelunch blood glucose closer to target (189 vs. 273 mg/dL on open loop, P = 0.009).

Conclusions: Closed-loop insulin delivery decreases the severity of overnight hyperglycemia without increasing the incidence of hypoglycemia. The therapy is better able to reestablish target glucose levels in advance of a subsequent meal. Younger children with type 1 diabetes may reap significant benefits from closed-loop therapy.

Trial registration: ClinicalTrials.gov NCT01421225.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Comparison of average (N = 10) open- and closed-loop glucose (A) and insulin delivery (B, left axis) and concentration (B, right axis) curves. MID, midnight.

References

    1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
    1. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011;7:385–395
    1. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2:27ra27.
    1. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010;375:743–751
    1. Steil GM, Palerm CC, Kurtz N, et al. The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab 2011;96:1402–1408
    1. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006;55:3344–3350
    1. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934–939
    1. Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997;20:22–25
    1. Wagner VM, Rosenbauer J, Grabert M, Holl RW, German Initiative on Quality Control in Pediatric Diabetology Severe hypoglycemia, metabolic control, and diabetes management in young children with type 1 diabetes using insulin analogs—a follow-up report of a large multicenter database. Eur J Pediatr 2008;167:241–242
    1. Bjørgaas M, Gimse R, Vik T, Sand T. Cognitive function in type 1 diabetic children with and without episodes of severe hypoglycaemia. Acta Paediatr 1997;86:148–153
    1. Ryan C, Vega A, Drash A. Cognitive deficits in adolescents who developed diabetes early in life. Pediatrics 1985;75:921–927
    1. Gandrud LM, Xing D, Kollman C, et al. The Medtronic Minimed Gold continuous glucose monitoring system: an effective means to discover hypo- and hyperglycemia in children under 7 years of age. Diabetes Technol Ther 2007;9:307–316
    1. DIAMOND Project Group Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med 2006;23:857–866
    1. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009;373:2027–2033
    1. Mauras N, Beck R, Xing D, et al. Diabetes Research in Children Network (DirecNet) Study Group A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. Diabetes Care 2012;35:204–210
    1. Loutseiko M, Voskanyan G, Keenan DB, Steil GM. Closed-loop insulin delivery utilizing pole placement to compensate for delays in subcutaneous insulin delivery. J Diabetes Sci Tech 2011;5:9
    1. Swan KL, Dziura JD, Steil GM, et al. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care 2009;32:240–244
    1. Swan KL, Weinzimer SA, Dziura JD, et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabetes Care 2008;31:44–46
    1. American Diabetes Association Standards of medical care in diabetes—2012. Diabetes Care 2012;35(Suppl. 1):S11–S63
    1. Gonder-Frederick L, Nyer M, Shepard JA, Vajda K, Clarke W. Assessing fear of hypoglycemia in children with type 1 diabetes and their parents. Diabetes Manag (Lond) 2011;1:627–639
    1. Kanderian SS, Weinzimer S, Voskanyan G, Steil GM. Identification of intraday metabolic profiles during closed-loop glucose control in individuals with type 1 diabetes. J Diabetes Sci Tech 2009;3:1047–1057
    1. Kanderian SS, Weinzimer SA, Steil GM. The identifiable virtual patient model: comparison of simulation and clinical closed-loop study results. J Diabetes Sci Tech 2012;6:371–379
    1. Steil GM, Clark B, Kanderian S, Rebrin K. Modeling insulin action for development of a closed-loop artificial pancreas. Diabetes Technol Ther 2005;7:94–108
    1. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282–1287

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir